Clinical trials: Ischemic Brain
Acute Stroke
Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells in Acute Ischemic Stroke
This study is a first-in-human assessment of safety of using umbilical cord mesenchymal stem cells (UCMSCs) in patients with Acute Ischemic Stroke via a combination of intra arterial (IA) and intravenous (IV) stem cell…
- Trial name
- NCT04434768
- Testing
- UMSC01
- Where
- Taiwan
- Volunteers
- 10 people
- Sponsor
- Ever Supreme Bio Technology Co., Ltd.
Acute Ischemic Stroke
Study to Evaluate The Safety and Efficacy of Balovaptan in Participants With Acute Ischemic Stroke at a High Risk of Developing Malignant Brain Edema
This study is designed to evaluate the safety, efficacy, and pharmacokinetics of balovaptan compared with placebo in participants with acute ischemic stroke (AIS) at risk of developing Malignant Cerebral Edema (MCE)
- Trial name
- NCT05399550
- Testing
- Balovaptan
- Where
- United States
- Sponsor
- Hoffmann-La Roche
Ischemic Stroke
Efficacy and Safety Evaluation of 3K3A-APC in Ischemic Stroke
The purpose of this study is to evaluate the efficacy and safety of intravenous doses of 3K3A-APC, a recombinant variant of human activated protein C (APC), in the treatment of acute ischemic stroke following treatment with…
- Trial name
- RHAPSODY-2 (NCT05484154)
- Testing
- 3K3A-APC
- Sponsor
- ZZ Biotech, LLC
Acute Ischemic Stroke
Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window (ImpACT-24A)
The primary objective of the study is to assess the safety and effectiveness of SPG stimulation with the ISS in patients with an acute ischemic stroke in the anterior circulation initiated within 24 hours from stroke onset.
- Trial name
- ImpACT-24A (NCT03767192)
- Testing
- Active Stimulation
- Where
- 8 sites in United States, Germany and 1 more
- Volunteers
- 327 people
- Sponsor
- BrainsGate
Cerebrovascular Accident
Rt-PA in the Treatment of Acute Ischemic Stroke
To collect additional confirmatory data on alteplase(rt-PA) in the European setting and to demonstrate that the treatment of patients between 3 and 4.30 hours of onset of symptoms of acute ischemic stroke with rt-PA compared to…
- Trial name
- NCT00153036
- Where
- 142 sites in Austria, Belgium and 17 more
- Volunteers
- 821 people
- Sponsor
- Boehringer Ingelheim
Acute Ischemic Stroke
A Clinical Trial of MT200605 for the Treatment of Acute Ischemic Stroke
MT200605 is an agonist of the receptor tyrosine kinase B (TrkB). It exerts brain-derived neurotrophic factor (BDNF)-like effects, protecting the structure and function of neural tissues in the brain.
- Trial name
- NCT07205328
- Testing
- MT200605
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Acute Ischemic Stroke (AIS)
A Phase I Clinical Trial Evaluating the Safety, Tolerability and Pharmacokinetics of AAPB for Injection
This is a Phase I clinical to evaluate the safety and tolerability of single and multiple intravenous infusions of AAPB at different doses over 7 consecutive days.
- Trial name
- AAPB (NCT06679998)
- Testing
- Single dose, AAPB by injection, intravenous drip., Multiple dosing, AAPB for injection, intravenous drip
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Jiangsu Kanion Pharmaceutical Co., Ltd
Stroke, Ischemia
A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)
The purpose of this study is to evaluate the safety and tolerability of 42037788 (CNTO 0007) in patients who have suffered a stroke.
- Conditions
- Stroke, Ischemia, Infarction
- Trial name
- NCT01273467
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Janssen Research & Development, LLC
Ischemic Stroke
The Efficacy of a Frequency-tuned Electromagnetic Field Treatment in Facilitating the Recovery of Subacute Ischemic Stroke Patients - a Pivotal Study (THE "EMAGINE" STUDY)
This is a multicenter study that will be conducted at approximately 20 centers. BQ 2.0 is a wearable medical device that produces and delivers non-invasive, extremely-low-intensity and low-frequency, frequency-tuned…
- Trial name
- BQ5 (NCT05044507)
- Testing
- BQ 2.0
- Where
- 15 sites in United States
- Volunteers
- 100 people
- Sponsor
- BrainQ Technologies Ltd.
Carotid Artery Disease, Stroke
Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy
The objective of the CANOPY trial is to assess the continued safety and effectiveness of the RX Acculink Carotid Stent System under commercial use in subjects at standard risk for adverse events from Carotid Endarterectomy (CEA)…
- Conditions
- Carotid Artery Disease, Stroke, Amaurosis Fugax, Transient Ischemic Attack (TIA)
- Trial name
- CANOPY (NCT01445613)
- Testing
- RX Acculink Carotid Stent System (RX Acculink)
- Where
- United States
- Volunteers
- 1,203 people
- Sponsor
- Abbott Medical Devices
Cerebral Stroke, Thrombosis, Deep Vein
A Study of Adverse Events and Suspected Adverse Drug Reactions in Patients Under Apixaban for Prevention of Stroke and Systemic Embolism With Non-Valvular Atrial Fibrillation and Venous Thromboembolic Events in Patients Who Have Undergone Elective Hip or Knee Replacement Surgery
To characterize and analyze the number, type and incidence of adverse events/suspected adverse drug reactions in patients treated with Apixaban, according to therapeutic indications approved in Mexico.
- Conditions
- Cerebral Stroke, Thrombosis, Deep Vein, Pulmonary Embolism
- Trial name
- NCT03804125
- Sponsor
- Pfizer
Acute Ischemic Stroke
A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects
This Phase 1 study is planned to establish the clinical safety and pharmacokinetics profile of multiple dose of LT3001 drug product and to investigate drug interactions of LT3001 with potential concomitant medications in healthy…
- Trial name
- NCT04809818
- Testing
- LT3001 drug product, Aspirin, Clopidogrel
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Lumosa Therapeutics Co., Ltd.
Cerebrovascular Accident
Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke (SENTIS)
The purpose of this study is to assess the safety and efficacy of the NeuroFlo™ catheter for use in patients with ischemic stroke.
- Trial name
- SENTIS (NCT00119717)
- Testing
- NeuroFlo™ catheter, Control
- Where
- 72 sites in United States, Austria and 8 more
- Volunteers
- 515 people
- Sponsor
- CoAxia
Stroke
Electroencephalograph for Detection of Acute Ischemic Stroke
The purpose of this study is Collecting data for an Electroencephalograph based algorithm for detection of onset and deterioration of Acute Ischemic Stroke by Comparison to NIHSS.
- Trial name
- NCT01737723
- Testing
- Neurokeeper stroke detector
- Where
- Israel
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Neurokeeper Technologies
Acute Ischemic Stroke
Efficacy of DLBS1033 in Patients With Acute Ischemic Stroke
This is a 3-arm, prospective, randomized, double-blind, and controlled clinical study, with 3 months of treatment to evaluate efficacy of DLBS1033 in bleeding profile and clinical outcome in patients with acute ischemic stroke…
- Trial name
- NCT01790997
- Testing
- DLBS1033, Aspirin, Clopidogrel
- Where
- Indonesia
- Volunteers
- 126 people
- Sponsor
- Dexa Medica Group
Acute Ischemic Stroke
ANAIS Study to Confirm the Safety and Performance of the ANA 5F Advanced Neurovascular Access®
Prospective, single-arm, multi-center study to assess the safety and performance of the ANA 5F Advanced Neurovascular Access®, in combination with a stent retriever in patients with acute ischemic stroke.
- Trial name
- ANAIS (NCT05409430)
- Testing
- Neurothrombectomy
- Where
- 3 sites in Spain
- Volunteers
- 43 people
- Sponsor
- Anaconda Biomed S.L.
Acute Ischaemic Middle Cerebral Artery Stroke
A Study to Evaluate the Efficacy and Safety of Piracetam on Aphasia After Acute Ischemic Cerebral Artery Stroke
The aim of this study was to confirm the efficacy of piracetam after 12 weeks of treatment on the aphasic status of subjects suffering from aphasia after acute ischemic middle cerebral artery stroke and having received their…
- Trial name
- NCT01883011
- Testing
- Piracetam
- Where
- 44 sites in Argentina, Austria and 13 more
- Volunteers
- 571 people
- Sponsor
- UCB S.A. - Pharma Sector
Stroke
Safety and Efficacy Study in Acute Ischaemic Stroke
A Phase II study to evaluate the safety and efficacy of five dose levels of study drug in acute ischaemic stroke
- Trial name
- VASST (NCT00144014)
- Testing
- V10153
- Where
- 28 sites in United States, Canada
- Volunteers
- 49 people
- Sponsor
- Vernalis (R&D) Ltd
Neuro ICU, Sub Arachnoid Hemorrhage
Comparison of Ultrasound Cerebral Perfusion Imaging With Routine Perfusion CT
The primary goal of neurocritical care is to prevent secondary brain injury, which worsens neurological outcomes. Because clinical monitoring is often insufficient due to the patient's condition and medical treatments, multimodal…
- Conditions
- Neuro ICU, Sub Arachnoid Hemorrhage, Neurological Complication, Cerebral Ischemia
- Trial name
- SCULPT (NCT07324421)
- Testing
- Ultrasound contrast agent (Contrast-enhanced ultrasound)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Resolve Stroke
Acute Ischemic Stroke
A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)
The purpose of this study is to determine if YM872 in combination with t-PA can reduce disability and brain damage from stroke. YM872 or placebo will be given as a continuous intravenous (iv) infusion for 24 hours.
- Trial name
- NCT00044057
- Testing
- YM872 (zonampanel), t-PA (alteplase)
- Where
- 118 sites in United States, Austria and 3 more
- Sponsor
- Astellas Pharma Inc